Overview
US biotechnology firm's 2025 net loss narrowed, beating analyst expectations
Collaboration revenue for 2025 surged, driven by Bristol-Myers Squibb agreement
Company completed $135 mln private placement, extending cash runway into Q1 2029
Outlook
Century expects to submit CNTY-813 IND in 4Q 2026, with initial clinical data in 2H 2027
Company expects CNTY-308 to enter the clinic in 2026, pending regulatory clearance
Century anticipates updated preliminary clinical data from the CARAMEL study in 2026
Result Drivers
COLLABORATION REVENUE - Surge in collaboration revenue attributed to Bristol-Myers Squibb agreement
LOWER R&D AND G&A COSTS - Decline in research and development and administrative expenses due to reduced personnel, manufacturing, and legal costs
Company press release: ID:nGNX7Qd8DN
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Collaboration Revenue | $109.16 mln | ||
FY Net Income | Beat | -$9.58 mln | -$14.72 mln (3 Analysts) |
FY Operating Income | Beat | -$17.27 mln | -$20.86 mln (3 Analysts) |
FY Basic EPS | -$0.14 | ||
FY Operating Expenses | $126.43 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Century Therapeutics Inc is $4.00, about 46.5% above its March 11 closing price of $2.73
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)